In this installment of the “How I treat ...” series in Blood, the authors outline their clinical algorithm to treat adult patients with relapsed Philadelphia chromosome negative acute lymphoblastic lymphoma (ALL). They note that “allogeneic HCT in second remission is the only curative approach and is the goal when feasible.” The authors note that although there is no standard chemotherapy regimen for relapsed ALL, there are approved agents available, including blinatumomab, nelarabine, and liposomal vincristine. They also discuss the use of monoclonal and cellular investigational therapies and recommend exploration through clinical trials in appropriate patients.
Review: Treatment Options for Adults with Relapsed or Refractory Ph- ALL
Jun 2015